摘要
目的:探讨非小细胞肺癌(NSCLC)患者外周血中转化生长因子β1(TGF-β1)水平与机体免疫功能变化及与NSCLC分期、病理类型的关系。方法:87例病理证实为NSCLC并依据2009年国际抗癌联盟和国际肺癌研究会公布的第7版肺癌国际分期法为Ⅰ～Ⅳ期的患者;42例健康人为对照组。应用酶联免疫吸附(ELISA)法检测空腹外周静脉血中TGF-β1含量。采用流式细胞仪检测外周血中CD3+、CD4+、CD8+、CD4+/CD8+和CD4+CD25+细胞比例,并进行分层分析。结果:NSCLC患者CD3+、CD4+、CD8+细胞比例显著低于对照组(P<0.01);TGF-β1含量和CD4+CD25+细胞比例显著高于对照组(P<0.01);NSCLCⅠ期和Ⅱ期患者CD3+、CD4+、CD8+细胞比例显著高于Ⅲ期和Ⅳ期患者(P<0.01);而TGF-β1水平和CD4+CD25+细胞比例显著低于Ⅲ期和Ⅳ期患者(P<0.01);但Ⅰ期和Ⅱ期之间、Ⅲ期和Ⅳ期之间差异无统计学意义(P>0.05)。在不同病理类型之间TGF-β1水平和CD3+、CD4+、CD8+、CD4+/CD8+和CD4+CD25+细胞比例均差异无统计学意义(P>0.05)。结论:NSCLC患者外周血中TGF-β1和CD4+CD25+水平与患者的免疫功能呈负相关,TNM分期越晚,机体细胞免疫功能越低,TGF-β1水平和CD4+CD25+细胞比例越高;但TGF-β1含量在NSCLC不同病理类型间差异无统计学意义。
Objective：To investigate the transforming growth factor β1 （TGF-β1） levels and changes of immune function with cancer stage.histological type of cancer in the non small cell lung carcinoma patients. Methods： A total of 87 hospitalized patients which were histological confirmed non-small cell lung carcinoma （NSCLC）, based on the 2009 International Union A- gainst Cancer （UICC） and the International Lung Cancer Research （IASLC） published the seventh edition of the international staging of lung cancer, staging into the group I-IV of patients; also included 42 cases of healthy control subjects. Enzyrae-linked immunosorbent assay （ELISA） in peripheral blood fasting TGF-β1 content. Peripheral blood by flow cytometry in CD3＋ , CD4＋ , CD8＋ , CD4＋ / CD8＋ and CD4＋ CD25＋ cell percentage, and stratified analysis. Results： NSCLC patients with CD3＋ , CD4＋ , CD8＋ cells was significantly lower than the controls （P（0.01）; TGF-β1 levels and CD4＋ CD25＋ cells was higher （P（0.01）; NSCLC patients with stage I and II CD3＋ , CD4＋ , CDS＋ cells was higher than in stage ]H and IV （P＇＋ 0.01） ; and TGF-β1 levels and CD4 ＋ CD25 ＋ cells was lower than in stage III and iV （P〈0.01） ; but I and II of room, III and IV was no significant difference between （P〉 0.05）. Between the different pathological types of TGF-β1 levels and CD3＋ , CD4＋ , CD8＋ , CD4＋/CD8＋ and CD4＋ CD25＋ cells was not significantly different （P＋〉 0.05）. Conclusions： NSCLC patients with the TGF- β1 and CD4＋ CD25 ＋ levels and the patient＇s immune function is a negative correlation, TNM stage later, the immune function, the lower, TGF-β1 levels and CD4＋ CD25 ＋ cells are higher; but TGF β1 levels in NSCLC are no difference between different pathological types.
出处
《中国临床医学》
2011年第5期571-574,共4页
Chinese Journal of Clinical Medicine
基金
国家自然科学基金(编号:30872555)
云南省科技厅应用基础研究项目(编号:2009ZC116M)
关键词
转化生长因子Β1
非小细胞肺癌
细胞免疫
Transforming growth factor-β1
Non-small cell lung carcinoma
Cellular immunity
